Related references
Note: Only part of the references are listed.Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Ken Ohmachi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance
Julia Horn et al.
ANNALS OF HEMATOLOGY (2012)
Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL)
Luigi Rigacci et al.
ANNALS OF HEMATOLOGY (2012)
Inhibitors of B-Cell Receptor Signaling for Patients With B-Cell Malignancies
Michael Y. Choi et al.
CANCER JOURNAL (2012)
Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy
Eva Walter et al.
LEUKEMIA & LYMPHOMA (2012)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
SYK inhibition and response prediction in diffuse large B-cell lymphoma
Shuhua Cheng et al.
BLOOD (2011)
Higher Response to Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Nongerminal Center B-Cell-Like Than in Germinal Center B-Cell-Like Phenotype
Francisco J. Hernandez-Ilizaliturri et al.
CANCER (2011)
Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial
Chaitra Ujjani et al.
FUTURE ONCOLOGY (2011)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy of bendamustine as salvage treatment in an heavily pre-treated Hodgkin lymphoma
Gianna Maria D'Elia et al.
LEUKEMIA RESEARCH (2010)
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma
Gaetano Corazzelli et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Bendamustine: Rebirth of an Old Drug
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Classification of lymphoid neoplasms: the microscope as a tool for disease discovery
Elaine S. Jaffe et al.
BLOOD (2008)
Diffuse Large B-Cell Lymphoma
Jonathan W. Friedberg et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2008)
GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma:: a phase II study
Andres Lopez et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
Rekha Harting et al.
CLINICAL LYMPHOMA & MYELOMA (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
Ulrich J. M. Mey et al.
CANCER INVESTIGATION (2006)
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
P Feugier et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma
E Weidmann et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
